Targeted Lung Cancer Therapy

Erlotinib

EGFR inhibitor used for advanced non-small cell lung cancer and pancreatic cancer.

Erlotinib is an oral targeted cancer therapy classified as an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It is used to treat non-small cell lung cancer (NSCLC) with specific EGFR mutations and pancreatic cancer in combination with gemcitabine. Erlotinib works by blocking signals that drive cancer cell growth and survival, slowing tumor progression and extending patient survival.

Ingredients dosages:

Frequency:

Quantity:

Not sure about dosages? Don't worry, your provider will adjust or confirm your selection after checkout.

Total

$0.00

AI Assessment
ai care membership.avif

AI Care Membership

Early members save on discounted pricing.

2 comprehensive appointments

2 comprehensive appointments

Additional provider visits

Additional provider visits

Personalized AI health analysis

Personalized AI health analysis

$41.58/month

Annual membership $499.00

$699.00

  1. 1

    Place Your Order

    Start by selecting your medication and checking out.You'll be charged for the medical provider review now and for the medication only once it’s approved by the provider.

  2. 2

    Complete a Quick Medical Questionnaire

    After checkout, we need you to answer questions about your symptoms, medical history, and current medications.

  3. 3

    Licensed Provider Review

    A licensed healthcare provider reviews your complete medical profile, ensuring this treatment is safe and appropriate for you.

  4. 4

    Personalized Treatment Plan

    Your provider may recommend an adjustment to your prescription based on your full medical profile before approving your treatment.

HIPAA Compliant
Certified Providers

  • Improves progression-free survival in patients with advanced NSCLC with EGFR mutations

  • Reduces tumor growth and delays disease progression in pancreatic cancer when combined with gemcitabine

  • Effective oral targeted therapy with manageable side effects compared to conventional chemotherapy

  • Provides symptom relief, including reduction in cough and breathlessness, for lung cancer patients

  • Erlotinib: Inhibits EGFR tyrosine kinase activity, blocking downstream signaling pathways that drive cancer cell proliferation and survival in EGFR mutation-positive tumors

  • Take once daily on an empty stomach (at least 1 hour before or 2 hours after food)

  • Do not crush or split the tablets; swallow whole with water

  • Avoid concomitant use with proton pump inhibitors to maintain absorption

  • Regular monitoring of liver function and skin toxicity is recommended during therapy